Roche has announced the global launch
(except US) of Elecsys Calcitonin, a new laboratory test for the
diagnosis and lifelong monitoring of medullary thyroid cancer patients
after thyroid surgery. This test is based on Calcitonin, a specific tumour
marker that can help diagnose medullary thyroid
carcinoma early, as elevated concentrations of calcitonin in the blood
are associated with the onset of this type of cancer.
Designed for use on Roche’s cobas modular analyser platform, Elecsys
Calcitonin offers healthcare professionals an integrated solution for
accurate diagnosis and reliable patient monitoring, significantly
improving medical decision-making and treatment planning.
Click here for more info
